Global Opioids Market, by Drug Class (Agonist (Codeine, Fentanyl, Meperidine, Methadone, Morphine, Hydrocodone, Diphenoxylate, Hydromorphone, Methylphenidate, Oxycodone, Oxymorphone) and Antagonist (Buprenorphine, Naloxone, Naltrexone, Methylnaltrexone, Nalbuphine)), by Therapeutic Application (Pain Management, Cough Treatment, Diarrhea Treatment), and by Geography - Trends and Forecast till 2025

  • To Be Published : Nov 2017 |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Opioids – Reducing body pain but increasing pain for regulatory authorities

Opioids are narcotics that act on opioid receptors to produce morphine-like effects. Medically they are primarily used for pain management and treatment of diarrhea and cough. Agonist and antagonist are the two types of Opioid drugs. Codeine, Fentanyl, Meperidine, Methadone, Morphine, Hydrocodone, Diphenoxylate, Hydromorphone, Methylphenidate, Oxycodone, and Oxymorphone are classified as agonists. Buprenorphine, Naloxone, Naltrexone, Methylnaltrexone, and Nalbuphine are classified as antagonists. Opioids are rampantly overused worldwide, owing to easy availability and the situation is more critical in developed countries, such as the U.S. This has led to government or regulatory intervention in sale and prescription of opioids in various countries. The prescription pattern of the drug is closely monitored by government and regulatory bodies. Moreover, stringent guidelines are published for opioids prescription along with public awareness about adverse side effects of opioid such as dependence on the drug on regular use. Furthermore, government bodies have directed drug-stores to limit opioids delivery and participate in government activates in addressing the opioid crisis.

The incidence of opioid prescription has increased rapidly in last two decades worldwide. However, the rate of prescription is much high in the U.S, owing to high prevalence of chronic pain and other related conditions. Moreover, majority of these prescriptions in the U.S are for patients addicted to this drug. According to World Drug Report 2017, 29.5 million people suffered from drug overuse disorder worldwide, of which around 70% were registered in the U.S. The U.S recorded around 59,000 to 65,000 deaths due to drug overdose in 2016, of which around two-thirds were due to opioids overuse.

The global opioids market was valued at US$ 28,252.3 million in 2016 and is expected to witness a CAGR of 5.3% over the forecast period (2016 - 2024).

Figure 1. Global Opioids Market, by Region, 2016 (US$ Mn)

opioids market

Source: Coherent Market Insights Analysis (2017)

Increasing incidence of chronic pain is expected to drive the opioids market growth

Incidences of chronic pain is on the rise across the globe, with the rate being much higher in developed economies such as the U.S., UK, Germany, and Canada. According to a study published by BMJ (British Medical Journal), in 2013, around one-third to one-half of the population in UK suffered from some kind of chronic pain. The situation is not quite different in other developed economies such as the U.S. and Japan. According to a study published in NCBI, in 2015, prevalence of chronic pain is estimated to be as high as 20% (one in five) in Japan. The aging population is rapidly increasing in all in developed economies, which is thus expected to further increase incidences of chronic pain, in turn increasing consumption of opioid drugs.

Cannabis as potential alternative for pain relief

Cannabis has recently gained attention from a diverse range of people, including medical professionals, independent health advocacy groups, and government organizations. Cannabis is projected to emerge as a potential alternative therapy to opioids, as it controls nausea associated with intake of opioid drugs, as well as vomiting and dizziness that often accompany severe, prolonged pain. Moreover, risk of addiction associated with cannabis intake is much lower as compared to that of opioids. A poll conducted by the New England Journal of Medicine, in 2013, found that 75% (3 out of 4) clinicians in the U.S. recommended the use of cannabis for hypothetical cancer patients. Currently, medical marijuana is legal in 28 states and the District of Columbia, even though it is illegal under federal law. According to a research published, in 2017, in Annals of Internal Medicine, cannabis, which is also called medical marijuana, is used for pain management for 45-85% cases. However, the same research argues that there is little evidence to show that cannabis helps control chronic pain. Hence, an urgent need is experienced for high-quality clinical trials to test the clinical efficacy of marijuana in pain management. If clinical trials prove marijuana effective beyond a reasonable doubt, it is expected to emerge as a replacement for opioids.

Some of the major players operating in the global opioids market are Purdue Pharma, Titan Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Janssen Pharmaceuticals, Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Egalet Corporation, Endo Pharmaceuticals Inc., Allergan, Plc, and Pfizer Inc.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.